Campbell & Co Investment Adviser’s Apellis Pharmaceuticals APLS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-53,540	Closed	-$1.21M	–	1119
2025 Q3	$1.21M	Buy	+53,540	New	+$1.25M	0.09%	343
2025 Q1	–	Sell	-11,258	Closed	-$359K	–	1019
2024 Q4	$359K	Buy	+11,258	New	+$339K	0.03%	785
2024 Q2	–	Sell	-38,024	Closed	-$2.24M	–	1036
2024 Q1	$2.24M	Buy	+38,024	New	+$2.42M	0.19%	117
2023 Q3	–	Sell	-9,850	Closed	-$897K	–	926
2023 Q2	$897K	Buy	9,850 +1,545	+19%	+$133K	0.16%	192
2023 Q1	$548K	Buy	+8,305	New	+$479K	0.1%	385
2022 Q4	–	Sell	-17,177	Closed	-$1.17M	–	759
2022 Q3	$1.17M	Buy	17,177 +11,650	+211%	+$689K	0.27%	95
2022 Q2	$250K	Buy	+5,527	New	+$252K	0.07%	526

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Campbell & Co Investment Adviser's APLS Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 53,540 shares — an estimated $1.21M sold.

Campbell & Co Investment Adviser first reported a position in APLS in Q2 2022 and held it in 7 quarters. The position peaked at $2.24M in Q1 2024. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 53,540 Apellis Pharmaceuticals shares in Q4 2025, an estimated $1.21M.
Campbell & Co Investment Adviser first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Campbell & Co Investment Adviser's Apellis Pharmaceuticals position peaked at $2.24M in Q1 2024.
279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.